AGTR1 and metabolic syndrome: Compared to other AT(1) receptor blockers telmisartan may have further additional beneficial effects in patients with the metabolic syndrome as suggested by this study and by a recent report of Zhang et al that have shown that that AT(1) receptor-mediated coronary constriction that is augmented in the prediabetic metabolic syndrome and contributes to impaired control of coronary blood flow is beneficially affected by telmisartan[38].